Yahoo Poland Wyszukiwanie w Internecie

Search results

1. www.idsociety.org › practice-guideline › covid-19-guideline-treatment-and-managementIDSA Guidelines on the Treatment and Management of Patients with...

   www.idsociety.org › practice-guideline › covid-19-guideline-treatment-and-management

   In this section, we discuss how to approach a patient suspected to have COVID-19 and how to apply the IDSA COVID-19 treatment guidelines to specific clinical syndromes. The detailed evidence appraisals and recommendations for each therapeutic agent can be found in the individual sections.

   • Paxlovid

     This website uses cookies. We use cookies to ensure that we...

   • Antigen Testing

     December 20, 2022. Version 2.0.0 has been released and...

   • Serology

     Serologic tests for severe acute respiratory syndrome...

   • Training and Resources

     Guideline Panelists; Clinical Practice Guidelines...

   • AMR Guidance 2.0

     This guidance document provides recommendations to...

   • Infection Prevention & Control

     IDSA submitted comments to FDA's draft guidance for industry...

   • Evaluation and Management Services

     Dr. Timothy Sullivan, Vice Chair of IDSA’s Coding & Payment...

   • State and Regional Societies

     Recognition. Listed as an “Affiliate of IDSA” on IDSA’s...

2. www.ncbi.nlm.nih.gov › pmc › articlesTherapeutic antibodies for COVID-19: is a new age of IgM, IgA and...

   www.ncbi.nlm.nih.gov › pmc › articles

   27 lut 2022 · Early humoral immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are dominated by IgM and IgA antibodies, which greatly contribute to virus neutralization at mucosal sites.

3. www.frontiersin.org › journals › immunologyA predictive model for disease severity among COVID-19 elderly...

   www.frontiersin.org › journals › immunology

   • Zapisane w pamięci cache

   29 lis 2023 · The present study first compared IgG subtypes between COVID-19 elderly patients and healthy individuals 60 years of age and older. As can be seen in Table 2, there were significant differences in four subtypes of IgG between the two groups (p<0.05).

4. pmc.ncbi.nlm.nih.gov › articles › PMC7833601Clinical applications of detecting IgG, IgM or IgA antibody for...

   pmc.ncbi.nlm.nih.gov › articles › PMC7833601

   Serological tests for specific antibodies against SARS-CoV-2, including immunoglobulin M (IgM), IgG and IgA antibodies, have been developed as supplementary diagnostic methods as they can provide information about recent or prior infection (Peeling et al., 2020).

5. bmcinfectdis.biomedcentral.com › articles › 10Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and...

   bmcinfectdis.biomedcentral.com › articles › 10

   • Zapisane w pamięci cache

   1 lip 2023 · Estimating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) -specific immunoglobulin G (IgG) immunoglobulin M (IgM) antibodies are increasingly important for tracking the spread of infection and defining herd immunity barrier and individual immunization levels in the ongoing coronavirus disease 2019 (COVID-19) pandemic.

6. www.ncbi.nlm.nih.gov › pmc › articlesEfficacy of COVID-19 treatments among geriatric patients: a...

   www.ncbi.nlm.nih.gov › pmc › articles

   1 cze 2022 · Hydroxychloroquine, dexamethasone, and remdesivir revealed greater side effects or inefficiency in geriatric patients with COVID-19. Favipiravir, bamlanivimab, baricitinib, and supportive therapy showed a decrease in viral load and improvement of clinical symptoms.

7. www.ncbi.nlm.nih.gov › pmc › articlesAntibody responses in COVID-19 patients - PMC - National Center...

   www.ncbi.nlm.nih.gov › pmc › articles

   11 wrz 2020 · Both N and S- specific IgM and IgG responses increased along with disease course in non-ICU patients, detectable among 75% of patients in the first week and reaching 94.7% and 100% respectively in the second and third weeks after symptom onset, while dynamic patterns for SARS-CoV-2 specific antibody responses (no matter N or S, IgM or IgG) were ...